Genentech, Inc.

Recurium IP Holdings, LLC

Seragon Pharmaceuticals, Inc.

Kalypsys, Inc.

Johns Hopkins University

Cytochroma Inc.

Aragon Pharmaceuticals, Inc.

Oxalurx, Inc.

University of California

Zeno Royalties & Milestones, LLC

Cyctochroma Inc.

Poseidon Innovation, LLC

F. Hoffmann-La Roche Ag

Opko Ireland Global Holdings, Limited

Mehmet Kahraman

Steven P Govek

Nicholas D Smith

Johnny Yasuo Nagasawa

Andiliy Gokching Lai

Kevin Duane Bunker

Jackaline Dalgard Julien

Joseph Robert Pinchman

Chad Daniel Hopkins

Celine Bonnefous

Deborah Helen Slee

Peter Qinhua Huang

James W Malecha

Gary H Posner

Stewart Alwyn Noble

Jeffrey H Hager

Edna Chow Maneval

Sergio G Duron

Uttam Saha

Andrew Shiau

Boliang Lou

Karensa L Douglas

Christopher D Bayne

Andrew K Lindstrom

Guy Oshiro

Cunxiang Zhao

Carmen K Robinson

Michael Sertic

Michael John Clare

Jun Liang

Nicholas Charles Ray

Xiaojing Wang

Daniel Fred Ortwine

Simon Charles Goodacre

Sunny Abraham

Mark R Herbert

Rakesh Kumar Sit

Daniel Lee Severance

Chuangxing Guo

Ayman Kabakibi

Mark Charles Grier

Robert E Davis

Jay A White

Sharada Shenvi Labadie

Birong Zhang

Allen Borchardt

Glenville Jones

Brant Clayton Boren

Andrew K Shiau

Qinhua Huang

Thomas A Leedom

Heung Bae Jeon

Michael J Bishop

Steve P Govek

Bethany Halford

Thomas Leedom

Jackaline D Julien

Carmen KM Robinson

Steward A Noble

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.

Compounds and methods for treating oxalate-related diseases

Disclosed are compounds of formula (I): and pharmaceutically acceptable salts thereof. The compounds of the invention are BDII-selective inhibitors of BET proteins, and have therapeutic potential for treating cancer, acute kidney disease, and viral infections, among other diseases.

Anticancer compounds

Disclosed herein are compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), and methods of using compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It) as an analgesic.

Analgesic compounds

Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.

Bicyclic compounds

Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

Spirocyclic compounds

Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Estrogen receptor modulators and uses thereof

Heterocyclic estrogen receptor modulators and uses thereof

Described herein are compounds that are estrogen receptor modulators of Formula (I): 

Growing community of inventors

La Jolla, CA, United States of America

Mehmet Kahraman